Skip to main content
Journal cover image

Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD

Publication ,  Conference
Harrison, S; Taub, R; Neff, G; Moussa, S; Alkhouri, N; Bashir, M
Published in: JOURNAL OF HEPATOLOGY
2022

Duke Scholars

Published In

JOURNAL OF HEPATOLOGY

EISSN

1600-0641

ISSN

0168-8278

Publication Date

2022

Volume

77

Start / End Page

S14 / S14

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Harrison, S., Taub, R., Neff, G., Moussa, S., Alkhouri, N., & Bashir, M. (2022). Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD. In JOURNAL OF HEPATOLOGY (Vol. 77, pp. S14–S14).
Harrison, Stephen, Rebecca Taub, Guy Neff, Sam Moussa, Naim Alkhouri, and Mustafa Bashir. “Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD.” In JOURNAL OF HEPATOLOGY, 77:S14–S14, 2022.
Harrison S, Taub R, Neff G, Moussa S, Alkhouri N, Bashir M. Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD. In: JOURNAL OF HEPATOLOGY. 2022. p. S14–S14.
Harrison S, Taub R, Neff G, Moussa S, Alkhouri N, Bashir M. Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD. JOURNAL OF HEPATOLOGY. 2022. p. S14–S14.
Journal cover image

Published In

JOURNAL OF HEPATOLOGY

EISSN

1600-0641

ISSN

0168-8278

Publication Date

2022

Volume

77

Start / End Page

S14 / S14

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences